Rett Syndrome

Rett syndrome is a neurodevelopmental disorder most often associated with a pathogenic variant in MECP2. It primarily affects girls and women, but boys and men can also have MECP2-related disorders, including rare presentations that meet criteria for Rett syndrome. The condition varies substantially from person to person; sex alone does not establish or rule out the diagnosis. GeneReviews: MECP2 Disorders

This page is educational. Diagnosis, treatment, emergency planning, nutrition, and communication support should be individualized by the person's clinical team.

Core clinical picture

In classic Rett syndrome, early development is followed by a period of regression, often beginning between 6 and 18 months. Loss or reduction of purposeful hand use and spoken language, gait difficulty, and repetitive hand movements are characteristic. Breathing irregularities, seizures, sleep disturbance, gastrointestinal problems, scoliosis, abnormal muscle tone, and growth or nutrition concerns can also occur. Atypical presentations may begin earlier, later, or with a different pattern. GeneReviews

Rett syndrome is not accurately described as a steadily degenerative disease. After regression, many people enter a period of relative stability and can continue to learn and communicate. Abilities and support needs can change across the lifespan.

Diagnosis

Classic and variant Rett syndrome are defined clinically by developmental history and characteristic features (including Neul and related criteria used as suggestive findings). A pathogenic or likely pathogenic MECP2 variant establishes a MECP2-related diagnosis when the phenotype is suggestive; molecular results must always be read with the clinical picture. A negative test or a variant of uncertain significance does not exclude clinical Rett syndrome, and other genetic or neurologic conditions can produce overlapping features. GeneReviews: MECP2 Disorders

Assessment may include:

• A detailed developmental and regression history.
• Neurologic and physical examination.
• Genetic counseling and appropriately selected molecular testing.
• Evaluation of seizures, breathing, sleep, growth, nutrition, gastrointestinal function, mobility, bone health, scoliosis, and cardiac rhythm when clinically indicated.
• Vision, hearing, motor-access, and communication assessment.

Coding systems change and may differ by jurisdiction. Confirm any diagnosis or billing code in the current official coding system rather than copying a code from this page.

Medical management

Care is multidisciplinary and symptom-specific. Common areas for surveillance include seizure control, nutrition and swallowing safety, constipation and reflux, breathing irregularities, sleep, scoliosis, mobility and contractures, bone health, pain, and QTc prolongation. New symptoms or loss of function should not automatically be attributed to Rett syndrome; the treating team should assess for other causes. Consensus guidelines across the lifespan

Trofinetide is approved by the US Food and Drug Administration for Rett syndrome in adults and children aged 2 years and older. It is not a cure and is not appropriate for every person. Diarrhea and vomiting were common adverse reactions in the trial supporting approval; treatment decisions belong with the prescriber and should use the current product information. FDA approval summary

Urgent medical evaluation may be needed for breathing difficulty, a prolonged or unusual seizure, choking or suspected aspiration, severe dehydration, acute loss of alertness, or another sudden change. Families should follow the person's existing emergency plan and local emergency guidance.

Communication and AAC

Limited speech does not mean limited understanding or an absence of communicative intent. Communication assessment should look for individual signals across gaze, facial expression, body movement, vocalization, gesture, symbols, writing, switches, and speech-generating technology. Partners should allow adequate response time and confirm meaning rather than assuming it.

International consensus guidance supports early access to communication intervention and a broad range of augmentative and alternative communication (AAC). Eye gaze is commonly useful in Rett syndrome, but it is not automatically the best or only access method. Vision, oculomotor control, positioning, fatigue, motor planning, sensory needs, environments, communication partners, and the person's preferences all affect access. Rett communication consensus ASHA AAC Practice Portal

A practical communication plan should:

• Preserve access to reliable low-tech communication when powered equipment is unavailable.
• Provide vocabulary for more than requesting, including refusal, consent, pain, social connection, questions, and self-advocacy.
• Make the system available across home, education, healthcare, and community settings.
• Train communication partners to model the system, recognize existing signals, wait, and repair breakdowns.
• Reassess access as posture, vision, motor control, fatigue, and daily environments change.
• Avoid requiring proof of specific cognitive, symbolic, or motor prerequisites before AAC is considered.

No fixed grid size, access method, device brand, or accuracy percentage is appropriate for everyone with Rett syndrome. Goals should be meaningful to the individual and measured in real communication contexts.

Education and participation

Educational planning should presume the capacity to participate and should not use speech or hand function as a proxy for learning. Accessible instruction may require extra response time, partner-supported scanning, eye-gaze access, switch access, adapted materials, positioning support, and coordination among the learner, family, educators, SLP, occupational therapist, physical therapist, vision specialists, and medical team.

Plans should address communication access throughout the day, not only during therapy sessions. Fatigue, seizures, pain, breathing irregularities, and motor demands can make performance inconsistent; inconsistency should prompt investigation and adaptation rather than withdrawal of communication opportunities.

Review priorities for an individual

• What communication signals are already reliable, and how do partners recognize them?
• Can the person communicate refusal, discomfort, pain, and an urgent need?
• Is AAC available and usable in every important setting?
• Are vision, seating, mounting, and access needs assessed together?
• Is there a backup method for device failure, fatigue, or acute illness?
• Have recent changes in communication or movement been medically evaluated?

Sources

1. Kaur S, Christodoulou J. MECP2 Disorders. GeneReviews. Revised December 4, 2025.
2. Fu C, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatrics Open. 2020;4:e000717. doi:10.1136/bmjpo-2020-000717.
3. Townend GS, et al. Development of consensus-based guidelines for managing communication of individuals with Rett syndrome. Augmentative and Alternative Communication. 2020;36(2):71-81. doi:10.1080/07434618.2020.1785009.
4. US Food and Drug Administration. FDA approves first treatment for Rett syndrome. March 10, 2023.
5. American Speech-Language-Hearing Association. Augmentative and Alternative Communication Practice Portal. Accessed July 21, 2026.